Stifel analyst Paul Matteis raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $94 from $78 and keeps a Buy rating on the shares. The firm continues to like the stock into a number of clinical catalysts in 2025 and the hypothalamic obesity launch in 2026, the analyst tells investors. Even with investors viewing HO as a roughly $1B opportunity, the firm thinks the range of outcomes skews to the upside as $1B “seems more like a floor” and greater than $2B worldwide “seems realistic,” the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Buy Rating for Rhythm Pharmaceuticals Driven by Promising IMCIVREE Outlook and Potential Market Expansion
- Rhythm Pharmaceuticals announces presentations on setmelanotide
- Buy Rating Affirmed for Rhythm Pharmaceuticals on Promising Setmelanotide Data and Positive Outlook
- Buy Rating for Rhythm Pharmaceuticals Driven by Promising Prospects of IMCIVREE and Expansion into Hypothalamic Obesity
- Robust Pipeline and Regulatory Progress Bolster Buy Rating for Rhythm Pharmaceuticals